enGene Holdings Inc.

enGene Holdings Inc. is a clinical-stage biotechnology company headquartered in Montreal, Quebec, focused on developing genetic medicines for oncology indications. The company operates through its subsidiary enGene, Inc., and is advancing therapies designed to address unmet treatment needs in specific cancer types. The company's primary focus is on bladder cancer, where it is developing detalimogene voraplasmid as a monotherapy for non-muscle invasive bladder cancer (NMIBC). The company also maintains a pipeline program designated LEGEND, currently in Phase 2 clinical development.

enGene operates as a clinical-stage entity with no marketed products generating commercial revenue. The company's business model is centered on advancing its pipeline candidates through clinical trials toward potential regulatory approval. With 81 full-time employees, the organization maintains operations at a scale typical for clinical-stage biotechnology firms in active development phases. The company is listed on Nasdaq and incorporated at the federal level in Canada, with its operations and research activities based in Montreal.